![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
---|---|
Information provided by: | Otsuka Pharmaceutical Development & Commercialization, Inc. |
ClinicalTrials.gov Identifier: | NCT00043758 |
The purpose of this study is to study the effects of tolvaptan on the size and function of the left heart chamber (ventricle) in patients with congestive heart failure (CHF)
Condition | Intervention | Phase |
---|---|---|
Congestive Heart Failure |
Drug: Tolvaptan |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
History of congestive heart failure
Study ID Numbers: | 156-01-232 |
Study First Received: | August 13, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00043758 |
Health Authority: | United States: Food and Drug Administration |
CHF |
Heart Failure Heart Diseases Dilatation, Pathologic |
Cardiovascular Diseases |